Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 28, 2023

Associations of tTMB and Mutational Status With Clinical Outcomes in Patients With Advanced PD-L1–Positive NSCLC Treated With Pembrolizumab vs Chemotherapy

Annals of Oncology


Additional Info

Annals of Oncology
Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
Ann. Oncol 2023 Apr 01;34(4)377-388, TSK Mok, G Lopes, BC Cho, DM Kowalski, K Kasahara, YL Wu, G de Castro, HZ Turna, R Cristescu, D Aurora-Garg, A Loboda, J Lunceford, J Kobie, M Ayers, MC Pietanza, B Piperdi, RS Herbst

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading